Strasbourg, France-based biotech firm Transgene (Euronext: TNG) has entered into a research, option and license deal with AstraZeneca (LSE: AZN) to co-develop five armed oncolytic vaccinia virus candidates.
Transgene, which is focused on the design and development of virus-based immunotherapies against cancers and infectious diseases, brings its viral platform Invir.IO to the table.
The French firm has been partnering actively in recent months, inking a deal with Tokyo-based NEC Corporation, and another with China’s Tasly Biopharmaceuticals (600535:SHH), in 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze